Abstract
Introduction: The options for drug therapy in persistent acromegaly are limited to somatostatin analogue treatment, more recently to pegvisomant, an inactive growth hormone and the oral use of dopamine agonists. Studies on growth hormone replacement therapy in men and women and a large number of experimental data demonstrate an inhibitory effect of estrogens on GH dependent IGF-1 secretion and circulating serum levels. Here we show that postmenopausal replacement therapy (HRT) cleary suppress tumor specific IGF-1 production.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Experimental and Clinical Endocrinology & Diabetes
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
